Navigation Links
Alzheimer's disease: Cutting off immune response promises new approach to therapy
Date:12/19/2012

The Bonn site of the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn are leading contributors.

The complex named "NLRP3 inflammasome" is composed of several proteins and plays a key role in the immune system. It resembles a fire alarm sensor that triggers a chain reaction when activated. As a result, immune cells are mobilized and substances that foster inflammation are released. This process can be triggered by infections, which are subsequently suppressed by the immune response. However, in the case of Alzheimer's disease, the activation of the molecular alarm may have negative consequences: nerve cells are damaged and die. Ultimately, this leads to the loss of brain function and mental capabilities in humans.

Alzheimer's disease is accompanied with deposits in the brain. That these so-called "plaques" have the capability to activate the NLRP3 inflammasome had already been identified by investigating individual cells. But the exact effect on the organism was unknown. "It was unclear what consequences an increased activity of the NLRP3 inflammasome could have on the brain," explains Prof. Michael Heneka, who conducts research at both, the DZNE and the University of Bonn. Working in a team with immune researcher Eicke Latz as well as with other colleagues, Heneka has now been able to show that the protein complex does in fact play a determining role in the development of Alzheimer's disease.

Studies involved humans and mice

The researchers collected a comprehensive chain of evidences: they examined both the brains of deceased Alzheimer patients and of mice who exhibited behavioural disorders that are typically associated with Alzheimer's disease. The researchers found an activated form of the NLRP3 inflammasome in both cases.

Looking at another group of mice, the scientists examined possibilities for suppressing inflammatory reactions. To achieve this, they removed the genes that trigger production of the NLRP3 inflammasome. Therefore, these mice were no longer able to synthesize the protein complex. As a result, the animals developed only relatively mild symptoms of the disease. Moreover, their brains showed only reduced amounts of the damaging plaques.

"We have stumbled upon a critical factor in the development process of Alzheimer's. Given these findings it appears to be a very promising possibility to block the activity of the inflammasome," comments Heneka. In his view, proper pharmaceuticals might be able to stop a chain reaction that would otherwise result in the inflammation of brain cells. "At present various options are being pursued to act upon the course of the disease," says the neuroscientist. "Our results points to a new possibility. Nevertheless, we are still in the process of doing basic research."

However, the group of scientists in Bonn is already making plans for the future. Eicke Latz's team, which also made significant contributions to the latest study, has already begun to search for active components that could block the NLRP3 inflammasome. "The testing of potential substances in the laboratory would be a next step. We hope to start as early as next year," says Heneka.


'/>"/>

Contact: Dirk Frger
presse@dzne.de
49-228-433-02260
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. New hope for treating Alzheimers Disease: A role for the FKBP52 protein
2. Therapies for spinal cord injury: On the cutting edge of clinical translation
3. U of Alberta researcher steps closer to understand autoimmune diseases
4. UCI-led study uncovers how Salmonella avoids the bodys immune response
5. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
6. Immune system implicated in prematurity complication
7. Key to immune system disease could lie inside the cheek
8. New immune defense enzyme discovered
9. New genetic mechanism of immune deficiency discovered
10. Carnegie Mellon fluorescent biosensor reveals mechanism critical to immune system amplification
11. Immune-response genes affecting breast tumor eradication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology: